Results

Zomedica Pharmaceuticals Corp.

11/26/2021 | Press release | Distributed by Public on 11/26/2021 15:33

Management Change/Compensation - Form 8-K

zom_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):November 19, 2021

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

Alberta, Canada

001-38298

N/A

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

100 Phoenix Drive, Suite 125, Ann Arbor, Michigan

48108

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (734) 369-2555

____________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, without par value

ZOM

NYSE American

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2021, Bruk Herbst was separated from employment as Chief Commercial Officer of Zomedica Corp. (the "Company").

In connection with his separation, Mr. Herbst entered into a separation and release agreement ( the "Separation Agreement") with the Company's wholly owned subsidiary, Zomedica Inc. ("ZI"). Under the terms of the Separation Agreement, Mr. Herbst is entitled to receive (i) the benefits to which he is entitled for a Termination Without Cause pursuant his employment agreement with the Company and ZI and (ii) certain equipment previously provided to him by the Company.

The Separation Agreement contains a release of claims, as well as an acknowledgment of Mr. Herbst's existing confidentiality and non-solicitation obligations, pursuant to his employment agreement with the Company and ZI (as modified by the Separation Agreement).

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibit

No.

Description

10.1

Confidential Separation Agreement and Release Agreement, dated November 19, 2021, between Zomedica Inc. and Bruk Herbst

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZOMEDICA CORP.

Date: November 26, 2021

By:

/s/ Ann Marie Cotter

Name:

Ann Marie Cotter

Title:

Chief Financial Officer

3